#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
proLékaře.cz

News

Biosimilar Bevacizumab in Patients with Non-Small Cell Lung Cancer

15. 9. 2021 Source: Oncological Treatment

Biosimilar drugs are essentially analogous to generics for biological medicines. The patent protection for the original bevacizumab product will expire in the European Union in 2022. Consequently, several companies have already embarked on developing a biosimilar molecule.

Position of Generic Drugs in Oncology: What Are Their Main Advantages?

Generics –⁠ as is well known –⁠ are products containing the same active substance as the original medicinal product, which can enter the market after the patent protection of the original drug has…
15. 9. 2021 Source: Oncological Treatment
pohotovost

Monocyte Distribution Width as a New Indicator of Sepsis in High-Risk Patients

Most septic patients are first encountered in the emergency department, where sepsis detection is often delayed, partly due to a lack of effective biomarkers. The study presented below evaluated the…
13. 9. 2021 Source: Because
sepse

New Hematological Biomarker for Early Diagnosis of Sepsis

Sepsis is one of the leading causes of mortality and healthcare expenditure worldwide. Early diagnosis and treatment of septic conditions improve patient prognosis. However, the initial symptoms of…
13. 9. 2021 Source: Because
Kašel

Interstitial Lung Processes and Their Fibrotic Progression

Interstitial lung processes (ILPs) include more than 200 clinical units that share diffuse involvement of lung tissue and thus have similar clinical, radiological, and functional findings. However,…
10. 9. 2021 Source: Progressive Interstitial Pulmonary Processes
klinicka studie

Evaluation of Continuity of Care in Patients with mCRC –⁠ Baseline Characteristics of Participants in the PROMETCO Study

During this year's World Congress of the European Society for Medical Oncology (ESMO) on gastrointestinal malignancies, the baseline characteristics of participants in the ongoing PROMETCO study, which...
9. 9. 2021 Source: Treatment of Gastrointestinal Carcinomas
kongres doktorov

Trifluridine/tipiracil in Real Clinical Practice –⁠ Current Data from Spain

Trifluridine/tipiracil is indicated for the treatment of patients with refractory metastatic colorectal cancer (mCRC), where clinical studies have shown it extends overall survival (OS) and progression-free...
9. 9. 2021 Source: Treatment of Gastrointestinal Carcinomas
CLL prezentace Abbvie ilustrační

Evaluation of Treatment Response in CLL

The size of lymph nodes, liver, spleen, blood cell counts, systemic symptoms... Changes in these indicators provide clear information on whether the disease of chronic lymphocytic leukemia (CLL) has progressed,...
9. 9. 2021 Source: Chronic Lymphocytic Leukemia
plíce

Idiopathic Pulmonary Fibrosis: Can This Disease Be Named More Precisely?

Much about idiopathic pulmonary fibrosis (IPF) is still unknown. Some experts would like to reclassify this disease. What classification options are available? What would a focus on the "progressive…
9. 9. 2021 Source: Progressive Interstitial Pulmonary Processes
statistiky business grafy kancelář práce studie

Brigatinib in the Therapy of ALK-Positive NSCLC in Patients Refractory to Crizotinib Therapy –⁠ Results of the Final Analysis of Clinical Studies

Previously published results of clinical studies have shown that in patients refractory to crizotinib therapy, the administration of brigatinib led to a high rate of therapeutic response (systemic…
9. 9. 2021 Source: Non-Small Cell Lung Cancer
PL_terapie_analyza_telo_technologie

Brigatinib in the Therapy of ALK-Positive NSCLC –⁠ First Results of the J-ALTA Study

Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor with broad and potent activity against ALK gene mutations causing resistance to ALK inhibitor therapy (ALKi). In patients refractory to…
9. 9. 2021 Source: Non-Small Cell Lung Cancer
srdce cevy cholesterol krev ateroskleroza

Ivabradine and/or Sacubitril/Valsartan in the Treatment of Heart Failure with Reduced Ejection Fraction

Ivabradine and sacubitril/valsartan are used in the second line of therapy for heart failure with reduced ejection fraction (HFrEF). The aim of the study presented below was to evaluate the…
7. 9. 2021 Source: Chronic Heart Failure and Lipidology
rano dělá den žena úsměv pohoda nálada

Variability of COPD Symptoms During the Day and Impact on Patients' Morning Routine –⁠ Survey Results

Chronic obstructive pulmonary disease (COPD) is viewed, unlike bronchial asthma, as a condition with a more chronic course and less variability of symptoms throughout the day. The study presented…
7. 9. 2021 Source: COPD
žena_astma_inhalace

Atectura® and Enerzair® from May 1, 2021 with Health Insurance Coverage

The fixed combination of indacaterol acetate (LABA) and mometasone furoate (ICS) Atectura® and the fixed triple combination, which in addition to these two substances also includes glycopyrronium…
2. 9. 2021 Source: Asthma under control
Schizofrenie_tvář_zlo

New Strategies in the Treatment of Schizophrenia

Schizophrenia was primarily associated with dopamine dysfunction. Previous and current treatments have mainly targeted the mesolimbic dopamine pathway in the CNS and D2 receptors. However, the cited…
30. 8. 2021 Source: Schizophrenia and Antipsychotics
1 … 70 71 72 73 74 … 115
Filter by speciality
Remove filters
Popular this week
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#